Genome Opinion is developing a data platform of clonal hematopoiesis with multiple sponsor-initiated clinical studies consisting of 12,000 human data.
Based on this data, we identified a novel disease indication associated with the clonal hematopoiesis biomarkers.
We are currently establishing animal models for each disease.
Our platform technology will be extended to include in vitro and in vivo models in addition to clinical data to select specific drugs for each indication, improving the efficacy of clinical trials.
